Reynoso Jamie L. sold $44K of CLOV

Reynoso Jamie L. (CEO, Medicare Advantage) sold 9,273 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.78 on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reynoso Jamie L.
Published Sep 15, 2026, 11:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 11:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
high confidence
Mentioned
$CLOV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The disclosed sale is small relative to insider holdings and unlikely to affect stock valuation.

02

Market read

Primary insider sale filing; low trading relevance but useful for monitoring insider activity.

03

What to watch

Potential tax planning or portfolio rebalancing unrelated to company fundamentals.

Relevance 2/10Novelty 5/10Timing: filing date 2026-09-15 (post-market)

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan indicates pre‑arranged sales.

Company-level read

Ticker impact

$CLOVNeutralHigh confidence
Context

CEO Reynoso Jamie L. sold 9,273 shares for $44,324.94 via a 10b5-1 plan, reducing his stake to 2,805,367 shares.

Expected impact

No material price movement expected; possible slight downward pressure.

Evidence & confidence

The sale amount is modest relative to total holdings and market cap; insider sales of this size rarely move the stock.

Market effects

Minimal effect on health‑tech sector; no broader industry signal.

None; transaction confined to US‑listed company.

Low; does not influence global markets.

Counterpoint

The sale could signal upcoming strategic changes not yet disclosed.

Key entities

  • Clover Health Investments, Corp.

    US‑listed health‑tech firm (ticker CLOV).

  • Reynoso Jamie L.

    CEO of Clover Health, reporting a sale of shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.